Literature DB >> 22676697

Optimizing the dose of dabigatran etexilate.

John Posner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22676697      PMCID： PMC3495138          DOI： 10.1111/j.1365-2125.2012.04353.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?

Authors:  Paul K L Chin; Jane W A Vella-Brincat; Murray L Barclay; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

2.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Marco Moia; Pier Mannuccio Mannucci
Journal:  N Engl J Med       Date:  2009-12-31       Impact factor: 91.245

3.  New options in anticoagulation for atrial fibrillation.

Authors:  Gregory J del Zoppo; Misha Eliasziw
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

4.  Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Authors:  John W Eikelboom; Lars Wallentin; Stuart J Connolly; Mike Ezekowitz; Jeff S Healey; Jonas Oldgren; Sean Yang; Marco Alings; Scott Kaatz; Stefan H Hohnloser; Hans-Christoph Diener; Maria Grazia Franzosi; Kurt Huber; Paul Reilly; Jeanne Varrone; Salim Yusuf
Journal:  Circulation       Date:  2011-05-16       Impact factor: 29.690

5.  Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

6.  Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.

Authors:  Joachim Stangier; Martin Feuring
Journal:  Blood Coagul Fibrinolysis       Date:  2012-03       Impact factor: 1.276

7.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.

Authors:  Joachim Stangier; Hildegard Stähle; Karin Rathgen; Reinhold Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.

Authors:  Elaine M Hylek; Carmella Evans-Molina; Carol Shea; Lori E Henault; Susan Regan
Journal:  Circulation       Date:  2007-05-21       Impact factor: 29.690

10.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dietmar Gansser; Willy Roth
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335
View more
  1 in total

1.  Is the dose of dabigatran really more predictable than warfarin?

Authors:  Daniel F B Wright; Hesham S Al-Sallami; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.